DTIM
Dutch Tumor Immunology Meeting

Thursday June 11th, 2026

09.00 – 09.30 **Registration & Coffee/Tea**

09.30 – 09.40 **Welcome**

09.40 - 10.40 **Oral presentation Session 1, chair: Marieke IJselsteijn**

Mike Eterman, Erasmus MC
Blocking Diacylglycerol Kinase enhances T-cell priming in tumor-draining lymph nodes bolstering the efficacy of anti-PD-1 therapy and peptide vaccination

Laia Gasull Celades, UMC Utrecht
Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells

Kumar Mangalam, Radboud UMC
Enhance membrane CD20 expression to improve immunotherapy response in B-cell non-Hodgkin

Rui Coelho, Erasmus MC
Actin-like protein 8 is a novel target for TCR-engineered T cells to treat colorectal cancer

10.40 - 11.05 *Break*

11:05 - 11:50 **Oral presentation Session 2, chair: Felicia Spitzer**

Anne Valk, Radboud UMC
Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity

Paul Niemöller, Erasmus MC
Combined chemotherapy and DNA damage response inhibition enhances innate immunity by cGAS/STING pathway activation in PDAC

Kyra Wagemans, Radboud UMC
Glucose deprivation in the tumor microenvironment reprograms cellular glycosylation and strengthens PD L1/PD 1 interactions

11.50-12.30 **Invited speaker**

Prof. Dr. Karen Dixon
University of Basel
"Identifying and Disrupting Neuro-Immune Circuits in Cancer"

12.30 – 13.00 **Pitch session 1**

1. Johannes Wellershoff, Leiden University Medical Center
Point-of-care manufacture of BOB1-TCR T cells for the treatment of B-cell malignancies

2. Dorine de Bont, UMC Utrecht
Engineering the next generation of γδ-TCR engineered T cell therapy: a non-viral approach

3. Nina Nooteboom, Leiden University Medical Center
Starting materials for point-of-care therapies: evaluating suitability of G-CSF-mobilized and cryopreserved apheresis material for adoptive T cell therapy manufacturing

4. Luc Magré, Erasmus MC
Blocking adenosine uptake restores intratumoral T cell function in hepatocellular carcinoma

5. Nadia Dubois, Radboud UMC
Optimizing a 35-colour spectral flow cytometry t-cell panel for immunophenotyping b-cell lymphoma patients post car t-cell therapy

6. Emma Heeremans, Amsterdam UMC
The tumour-stroma sialoglycan immune checkpoint: Siglec-7/9 ligand discovery and investigation of Siglec-7/9 membrane dynamics in pancreatic ductal adenocarcinoma

7. Felicia Spitzer, Leiden University Medical Center
Boosting Neoepitope Cancer Vaccine Efficacy via Cationic Liposome Delivery

8. Esther Fernández Merino, Radboud UMC
Optimizing HPC-derived dendritic cell vaccination for clinical translation

13.00 – 14.00 *Lunch*

14.00 - 15.00 **Oral presentation Session 3, chair: Diana Mittag**

Leyma Wardak, Sanquin Research Amsterdam
Generating and improving tumor-reactive TIl products for pediatric neuroblastoma

Ida van der Peet, UMC Utrecht
Unleashing the power of neutrophils to tackle Neuroblastoma: combination of CD47 blockade and IgA activation in one bispecific molecule

Teuntje Poortvliet, Leiden University Medical Center
Toward Better Preclinical Models: Improved Persistence and Tumor Control of Human T Cells in Cytokine-Humanized NSG Mice

Huang Shaozhuo, Erasmus MC
Live tracking of T-cell behavior in patient-derived 3D tumoroids

15.00 – 15.30 **Pitch session 2**

1. Imke van Rossum, Radboud UMC
Proximity labeling for cell surface proteomics

2. Chiara Scrocciolani, Department of Mechanical Engineering, Politecnico di Milano
3D Bioprinting of High-Grade Serous Ovarian Cancer Cells: Bioink Formulation and Printability Assessment Beyond the One-Size-Fits-All Approach

3. Francesca Tregnaghi, Radboud UMC
Unraveling the interplay among sialoglycan multivalency, Siglec-7/-9 membrane organization and cell signalling

4. Roos Wagensveld, Amsterdam UMC
Deciphering the sialic acid-Siglec immune inhibitory pathways in melanoma to enhance neoadjuvant immunotherapy response prediction

5. Cor Berrevoets, Erasmus MC
Chimeric TCRs to create novel T cell products: a critical role for mutated CD3e

6. Maria Lysandrou, University of Groningen
Structure-guided tuning of a Trastuzumab-based Chimeric antigen receptor enables tumor-Selective targeting with improved safety and preserved efficacy for HER2-positive breast cancer

7. Beau van Hulst, Leiden University Medical Center
Dissolvable microneedle arrays containing self-adjuvanting-peptide vaccines effectively induce cancer-specific T cells

8. Serena Vegna, Netherlands cancer Institute
Tumor niche-dependent macrophage reprogramming governs response to senescence-inducing therapy in liver cancer

15.30 – 16.10 *Coffee + check-in hotel*

16.10 – 17.25 **Oral presentation Session 4, chair: TBD**

Eugenia Cambiaso, UMC Utrecht
Every Component Matters: Examining the impact of the extracellular matrix on CAR T cell functionality in Multiple Myeloma

Jairo Lommen, UMC Utrecht
Engineered γ9δ2 T-Cell Receptors Enhance Targeting of Phosphoantigen-Driven Butyrophilin Complexes Across Cancer Therapeutic Formats

Douwe Samplonius, University of Groningen
ReTARG fusion proteins selectively redirect the cytotoxic activity of human CMV-specific T cells towards cancer cells and enhance the efficacy of CAR T cell approaches

Bart Spils, Radboud UMC
Engineering Stem Cell-derived NK cells with Chimeric Antigen Receptors and Transpresented IL-15 for Immunotherapy of Acute Myeloid Leukemia

Corine Pleijte, UMC Utrecht
Engineering BCMA CAR T-cells for myeloma-targeted cargo delivery – Towards clinical application

17:25 – 17:40 *Break*

17.40 – 18.20 **Invited speaker**

Prof. Dr. Reno Debets
Erasmus Medical Center
"T-cell engineering to move adoptive therapy forward"

18.20 – 19.00 **Invited speaker**

Prof. Dr. Leila Akkari
The Netherlands Cancer Institute
"From Diversity to Dependency: Plasticity and State Evolution of Myeloid Cells in Cancer"

19.00 - 21.00 *Dinner*

21.00 - 21.40 **Invited speaker**

Dr. Johannes Textor
Radboud University Medical Center
"Generative AI and the Language of the Immune Systems"

21.40 - 00.00 *Networking*

Friday June 12th, 2026

08.30 - 09.45 **Oral presentation Session 5, chair: Rieneke van de Ven**

Disha Shantilal Vadgama, Erasmus MC
Neutralization of the IL12/IL23 p40 subunit reduces immune checkpoint blockade (ICB)-induced toxicity without compromising antitumor efficacy

Hamdy Warda, Erasmus MC
New class of neo-antigens derived from APOBEC3 mutagenesis in breast cancer

Paula van Royen, The Netherlands Cancer Institute
Cytotoxic ieILC1 cells determine outcome of PD-(L)1 blockade in microsatellite instable cancers

Saskia Vijver, UMC Utrecht
The scavenger receptor MARCO is a novel ligand for the immune inhibitory receptor LAIR-1 and regulates LAIR-1 function in cis

Luc Margé, Erasmus MC
A novel PD-1 targeted IL-12 mutein construct to specifically activate intratumoral T cells

09.45 – 10.25 **Invited speaker**

Dr. Stefan Nierkens
University Medical Center Utrecht
"Same CAR, Different Outcome: Host Determinants of CAR-T Cell Efficacy"

10.25 – 10.55 *Coffee/Tea Break + check-out hotel*

10.55 – 11.40 **Oral presentation Session 6, chair: Iris Hagemans**

Laura Hooijmaijers, Radboudumc
Scalable bioreactor-based manufacturing of CD34+ progenitor-derived EpCAM-CAR-NK cells targeting ovarian cancer

Georgia Koutsoumpli, Leiden University Medical Center
T-Cell Receptors For Four New Hematopoietic-Restricted Minor Histocompatibility Antigens To Target Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Farid Keramati, UMC Utrecht
Functional γδT-omics pipeline reveals compartmentalization of Vδ1⁺ T cell migration, tumor-reactivity, and clonality in human colorectal cancer

11.40 - 12.20 **Invited speaker**

Prof. Dr. Joke Den Haan
Amsterdam University Medical Center
"Improving cancer vaccine efficacy by targeting to APCs"

12.20 – 12.30 **AIO Award Ceremony & Closure**

12.30 - … *Lunch 2GO*

Miltenyi Biotec

NWO

Many thanks to the sponsors of DTIM 2026!

Please Note; Selected abstract-presenters have exactly 15 minutes to present their data, including a few minutes discussion. Please make sure your presentation is on the computer before the session starts.
Presentations during the Pitch-sessions are exactly 3 minutes with a 5 min general discussion at the end of the session.